Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Factor xia protease inhibition: MerckRecent Research Landscape

Uncontrolled coagulation cascades during surgery or trauma lead to life-threatening thrombosis and high hospital costs. These innovations engineer specific quinoline-based molecular scaffolds to selectively block Factor XI activation, mitigating bleeding risks associated with traditional anticoagulants.

What technical problems is Merck addressing in Factor xia protease inhibition?

Uncontrolled pathological thrombus formation

(4)evidences

Excessive activation of the intrinsic coagulation pathway leads to life-threatening vascular occlusion. Preventing this specific activation stage limits clot propagation without severely compromising essential primary hemostasis.

Excessive clinical bleeding risk

(3)evidences

Excessive activation of the intrinsic coagulation pathway leads to life-threatening vascular occlusion. Targeting Factor XI minimizes thrombotic risk without compromising essential hemostasis.